NRX Pharmaceuticals Inc.-CW22NRXPWPreferred / convertible
13F holders, Q2 2025 (June 30)3holders −1
0new positions
1sold out
$0.09avg. 13F price*
At the end of Q2 2025, 3 institutions reported holding NRX Pharmaceuticals Inc.-CW22 (NRXPW) in their 13F filings, down 1 from Q1 2025. 0 opened new positions and 1 sold out. The largest holders were Truist Financial Corp. ($3K), Wolverine Asset Management LLC ($2K) and UBS Group AG ($128).
- Company
- NRX Pharmaceuticals Inc.-CW22
- CUSIP
- 629444118
- Latest filing quarter
- Q1 2026
History
Number of 13F holders
Total Exit/New Position Q1 2025 → Q2 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 1 | $1K |
All 13F filers, Q1 2025 → Q2 2025: 1,968 shares bought and 13,967 shares sold, net −11,999 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 3 holders
| Truist Financial Corp. | — | No change | 38,965 | $3K |
| Wolverine Asset Management LLC | — | Add +7.4% | 21,778 | $2K |
| UBS Group AG | — | Add +45.4% | 1,500 | $128 |
"% of holder's portfolio" is NRXPW's weight in each manager's 13F, not the share of NRX Pharmaceuticals Inc.-CW22 the manager owns.